30
Participants
Start Date
August 30, 2024
Primary Completion Date
September 30, 2027
Study Completion Date
September 30, 2027
Efgartigimod PH20 SC - prefilled syringe
Subcutaneous efgartigimod PH20 SC given by prefilled syringe
Placebo PH20 SC - prefilled syringe
Subcutaneous placebo PH20 SC given by prefilled syringe
RECRUITING
Allgemeines Krankenhaus der Stadt Wien (AKH Wien) - Medizinischer Universitätscampus, Vienna
RECRUITING
Universitair Ziekenhuis Leuven (UZ Leuven) - Campus Gasthuisberg, Leuven
RECRUITING
Universitair Ziekenhuis (UZ) Gent, Ghent
RECRUITING
Charité - Universitätsmedizin Berlin, Berlin
RECRUITING
Universitätsklinikum Hamburg-Eppendorf, Hamburg
RECRUITING
Virginia Commonwealth University (VCU) Medical Center Hume-Lee Transplant Center, Richmond
RECRUITING
Duke University Hospital, Durham
RECRUITING
Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital de Rangueil, Toulouse
RECRUITING
Centre Hospitalier Universitaire (CHU) de Bordeaux - Hôpital Pellegrin, Bordeaux
RECRUITING
University of Alabama at Birmingham (UAB) Hospital, Birmingham
RECRUITING
Centre Hospitalier Universitaire (CHU) de Grenoble Alpes - Hôpital Michallon, La Tronche
RECRUITING
The Ohio State University Wexner Medical Center, Columbus
RECRUITING
Cedars-Sinai Medical Center, Los Angeles
RECRUITING
University of Washington Medical Center, Seattle
RECRUITING
London Health Sciences Centre, London
RECRUITING
Institut klinicke a experimentalni mediciny (IKEM), Prague
RECRUITING
Universitaetsklinikum Carl Gustav Carus Dresden, Dresden
RECRUITING
Hospital Del Mar, Barcelona
RECRUITING
Hospital Universitario Vall d'Hebron, Barcelona
RECRUITING
Hospital Universitario de Bellvitge, Barcelona
Lead Sponsor
argenx
INDUSTRY